Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Etofylline→

Etofylline Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
519-37-9
Molecular formula
C9H12N4O3
Molecular weight
224.2166 g/mol
Drug class
Methylxanthine bronchodilatortheophylline analogue
Mechanism of action
Produces bronchodilation through methylxanthine pharmacology, including phosphodiesterase inhibition and adenosine-receptor antagonism, increasing intracellular cyclic AMP in bronchial smooth muscle.
Indications / reported uses
  • Historically used for symptomatic relief of bronchospasm in asthma and other obstructive airway diseases in countries where etofylline-containing products remain authorised; fixed combinations with theophylline have formulation-specific safety considerations

Sources: NLM MeSH — Etofylline · PubMed — Etofylline bronchodilator pharmacology · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Etofylline Environmental Risk Assessment (ERA) (the Etofylline ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.